IRLAB’s annual report for 2020 is now available on the company’s website

April 15, 2021 Regulatory

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the annual report for 2020 is published on In addition, the company’s website has been visually updated.

Read More >

IRLAB’s nomination committee proposes Martin Nicklasson as new board member and provides their proposal

April 8, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the nomination committee has provided their proposal and motivated opinion ahead of the annual general meeting 2021. Martin Nicklasson is proposed as a new board member. Martin Nicklasson has extensive experience from the international pharmaceutical industry, primarily from executive positions within AstraZeneca, Pharmacia, Biovitrum and Sobi as well as a board member in several life science companies.

Read More >

IRLAB’s drug candidate mesdopetam’s mechanism of action receives confirmation by independent scientists

March 25, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that independent scientists have confirmed that the dopamine D3 receptor (D3R) is a highly promising drug target with therapeutic potential in levodopa-induced dyskinesia, especially when the receptor’s unique signaling properties are taken into account. IRLAB’s mesdopetam is currently the most advanced D3R antagonist compound in the global neurology pipeline. It is used in the scientific article to exemplify a compound that could have an impact on the management of anumber of disorders marked by aberrant D3R activity. The article was published in the scientific journal Biomedicines in March 2021.

Read More >

IR contact

Viktor Siewertz, CFO
+46(0)72 710 70 70